GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy

Frank-Andre Siebert; Christian Kirisits; Taran Paulsen Hellebust; Dimos Baltas; Frank Verhaegen; Saskia Camps; Bradley Pieters; Gyorgy Kovacs; Bruce Thomadsen

doi:10.1016/j.radonc.2020.02.024

GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy

Frank-Andre Siebert^*, Christian Kirisits, Taran Paulsen Hellebust, Dimos Baltas, Frank Verhaegen, Saskia Camps, Bradley Pieters, Gyorgy Kovacs, Bruce Thomadsen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Ultrasound (US) is an important imaging modality in brachytherapy (BT). In particular for low-dose-rate (LDR) and high-dose-rate (HDR) prostate implants transrectal ultrasound (TRUS) is widespread. Besides the common use of US for prostate implants, US can also be applied in gynecological and anal cancer therapies as examples amongst others.

The BRAPHYQS (BRAchytherapy PHYsics Quality assurance System) and UroGEC (urology) working groups of GEC-ESTRO (GEC: Groupe Europeen de Curietherapie, committee of ESTRO: European SocieTy for Radiotherapy & Oncology) elaborated upon guidelines describing quality assurance (QA) methods for US in BT. The total quality management (QM) for the unit includes acceptance testing, commissioning and periodic image testing. In 2008, the AAPM (American Association of Physicists in Medicine) published the TG (Task group) 128 report. Whereas the TG 128 focuses on US systems and prostate BT, the current recommendations also cover tests for stepping devices and include other interstitial or intracavitary treatment sites in BT, such as anal implants and gynecological BT. The recommendations presented herein do not replace regular maintenance for the US devices performed by the vendor. They are the QA of US in BT but are not sufficient for the whole maintenance of medical US devices. Moreover, national regulations and recommendations should also be followed. For the tests presented in this report tolerances or action limits are given.

These recommendations explain practical test procedures of US devices in BT. They will help the clinics to perform a high level of quality in the use of US for BT in Europe. (C) 2020 Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	51-56
Number of pages	6
Journal	Radiotherapy and Oncology
Volume	148
DOIs	https://doi.org/10.1016/j.radonc.2020.02.024
Publication status	Published - Jul 2020

Keywords

Ultrasound
Brachytherapy
Quality assurance
Stepping device
GUIDED ADAPTIVE BRACHYTHERAPY
TRANSRECTAL ULTRASOUND
CANCER
CT

Access to Document

10.1016/j.radonc.2020.02.024

Cite this

@article{57b2dc32af694dd5906633772fbc0b2e,

title = "GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy",

abstract = "Ultrasound (US) is an important imaging modality in brachytherapy (BT). In particular for low-dose-rate (LDR) and high-dose-rate (HDR) prostate implants transrectal ultrasound (TRUS) is widespread. Besides the common use of US for prostate implants, US can also be applied in gynecological and anal cancer therapies as examples amongst others.The BRAPHYQS (BRAchytherapy PHYsics Quality assurance System) and UroGEC (urology) working groups of GEC-ESTRO (GEC: Groupe Europeen de Curietherapie, committee of ESTRO: European SocieTy for Radiotherapy & Oncology) elaborated upon guidelines describing quality assurance (QA) methods for US in BT. The total quality management (QM) for the unit includes acceptance testing, commissioning and periodic image testing. In 2008, the AAPM (American Association of Physicists in Medicine) published the TG (Task group) 128 report. Whereas the TG 128 focuses on US systems and prostate BT, the current recommendations also cover tests for stepping devices and include other interstitial or intracavitary treatment sites in BT, such as anal implants and gynecological BT. The recommendations presented herein do not replace regular maintenance for the US devices performed by the vendor. They are the QA of US in BT but are not sufficient for the whole maintenance of medical US devices. Moreover, national regulations and recommendations should also be followed. For the tests presented in this report tolerances or action limits are given.These recommendations explain practical test procedures of US devices in BT. They will help the clinics to perform a high level of quality in the use of US for BT in Europe. (C) 2020 Elsevier B.V. All rights reserved.",

keywords = "Ultrasound, Brachytherapy, Quality assurance, Stepping device, GUIDED ADAPTIVE BRACHYTHERAPY, TRANSRECTAL ULTRASOUND, CANCER, CT",

author = "Frank-Andre Siebert and Christian Kirisits and Hellebust, {Taran Paulsen} and Dimos Baltas and Frank Verhaegen and Saskia Camps and Bradley Pieters and Gyorgy Kovacs and Bruce Thomadsen",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = jul,

doi = "10.1016/j.radonc.2020.02.024",

language = "English",

volume = "148",

pages = "51--56",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy

AU - Siebert, Frank-Andre

AU - Kirisits, Christian

AU - Hellebust, Taran Paulsen

AU - Baltas, Dimos

AU - Verhaegen, Frank

AU - Camps, Saskia

AU - Pieters, Bradley

AU - Kovacs, Gyorgy

AU - Thomadsen, Bruce

PY - 2020/7

Y1 - 2020/7

N2 - Ultrasound (US) is an important imaging modality in brachytherapy (BT). In particular for low-dose-rate (LDR) and high-dose-rate (HDR) prostate implants transrectal ultrasound (TRUS) is widespread. Besides the common use of US for prostate implants, US can also be applied in gynecological and anal cancer therapies as examples amongst others.The BRAPHYQS (BRAchytherapy PHYsics Quality assurance System) and UroGEC (urology) working groups of GEC-ESTRO (GEC: Groupe Europeen de Curietherapie, committee of ESTRO: European SocieTy for Radiotherapy & Oncology) elaborated upon guidelines describing quality assurance (QA) methods for US in BT. The total quality management (QM) for the unit includes acceptance testing, commissioning and periodic image testing. In 2008, the AAPM (American Association of Physicists in Medicine) published the TG (Task group) 128 report. Whereas the TG 128 focuses on US systems and prostate BT, the current recommendations also cover tests for stepping devices and include other interstitial or intracavitary treatment sites in BT, such as anal implants and gynecological BT. The recommendations presented herein do not replace regular maintenance for the US devices performed by the vendor. They are the QA of US in BT but are not sufficient for the whole maintenance of medical US devices. Moreover, national regulations and recommendations should also be followed. For the tests presented in this report tolerances or action limits are given.These recommendations explain practical test procedures of US devices in BT. They will help the clinics to perform a high level of quality in the use of US for BT in Europe. (C) 2020 Elsevier B.V. All rights reserved.

AB - Ultrasound (US) is an important imaging modality in brachytherapy (BT). In particular for low-dose-rate (LDR) and high-dose-rate (HDR) prostate implants transrectal ultrasound (TRUS) is widespread. Besides the common use of US for prostate implants, US can also be applied in gynecological and anal cancer therapies as examples amongst others.The BRAPHYQS (BRAchytherapy PHYsics Quality assurance System) and UroGEC (urology) working groups of GEC-ESTRO (GEC: Groupe Europeen de Curietherapie, committee of ESTRO: European SocieTy for Radiotherapy & Oncology) elaborated upon guidelines describing quality assurance (QA) methods for US in BT. The total quality management (QM) for the unit includes acceptance testing, commissioning and periodic image testing. In 2008, the AAPM (American Association of Physicists in Medicine) published the TG (Task group) 128 report. Whereas the TG 128 focuses on US systems and prostate BT, the current recommendations also cover tests for stepping devices and include other interstitial or intracavitary treatment sites in BT, such as anal implants and gynecological BT. The recommendations presented herein do not replace regular maintenance for the US devices performed by the vendor. They are the QA of US in BT but are not sufficient for the whole maintenance of medical US devices. Moreover, national regulations and recommendations should also be followed. For the tests presented in this report tolerances or action limits are given.These recommendations explain practical test procedures of US devices in BT. They will help the clinics to perform a high level of quality in the use of US for BT in Europe. (C) 2020 Elsevier B.V. All rights reserved.

KW - Ultrasound

KW - Brachytherapy

KW - Quality assurance

KW - Stepping device

KW - GUIDED ADAPTIVE BRACHYTHERAPY

KW - TRANSRECTAL ULTRASOUND

KW - CANCER

KW - CT

U2 - 10.1016/j.radonc.2020.02.024

DO - 10.1016/j.radonc.2020.02.024

M3 - Article

C2 - 32335363

SN - 0167-8140

VL - 148

SP - 51

EP - 56

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

ER -